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Leukocyte TLR5 deficiency inhibits 
atherosclerosis by reduced 
macrophage recruitment and 
defective T-cell responsiveness
Guilielmus H.J.M. Ellenbroek1, Gijs H.M. van Puijvelde2, Adam A. Anas4, Martine Bot2, 
Miriam Asbach2, Arjan Schoneveld1, Peter J. van Santbrink2, Amanda C. Foks2, Leo Timmers5, 
Pieter A. Doevendans5, Gerard Pasterkamp1,6, Imo E. Hoefer1,6, Tom van der Poll3,4, 
Johan Kuiper2 & Saskia C.A. de Jager1,2
Toll-like receptors (TLR) provide a critical link between innate and adaptive immunity, both important 
players in atherosclerosis. Since evidence for the role of TLR5 is lacking, we aimed to establish this 
in the immune axis of atherosclerosis. We assessed the effect of the TLR5-specific ligand Flagellin on 
macrophage maturation and T-cell polarisation. Next, we generated TLR5−/−LDLr−/− chimeras to 
study the effect of hematopoietic TLR5 deficiency on atherosclerosis formation. Flagellin stimulation 
did not influence wildtype or TLR5−/− macrophage maturation. Only in wildtype macrophages, 
Flagellin exposure increased MCP-1 and IL6 expression. Flagellin alone reduced T-helper 1 proliferation, 
which was completely overruled in the presence of T-cell receptor activation. In vivo, hematopoietic 
TLR5 deficiency attenuated atherosclerotic lesion formation by ≈25% (1030*103 ± 63*103 vs. 
792*103 ± 61*103 μm2; p = 0.013) and decreased macrophage area (81.3 ± 12.0 vs. 44.2 ± 6.6 μm2; 
p = 0.011). In TLR5−/− chimeric mice, we observed lower IL6 plasma levels (36.4 ± 5.6 vs. 15.1 ± 2.2 pg/
mL; p = 0.003), lower (activated) splenic CD4+ T-cell content (32.3 ± 2.1 vs. 21.0 ± 1.2%; p = 0.0018), 
accompanied by impaired T-cell proliferative responses. In conclusion, hematopoietic TLR5 deficiency 
inhibits atherosclerotic lesion formation by attenuated macrophage accumulation and defective T-cell 
responsiveness.
Atherosclerosis is a progressive multi-factorial disease affecting middle-sized and large arteries. It is the main cul-
prit in the development of ischemic heart and cerebrovascular disease, together responsible for 29% of all deaths 
worldwide in 20131. Although initially thought to be exclusively caused by lipids and risk factors such as diabetes, 
hypertension and smoking2, it is now generally acknowledged that inflammation plays a critical role in athero-
sclerosis3,4. Migration of leukocytes into the vessel wall is an essential step in atherosclerotic lesion initiation and 
progression5,6. Hence, inhibition or prevention of leukocyte recruitment towards the vessel wall may prevent 
or reduce plaque development. In addition to the recruitment of leukocytes, it has been shown that immune 
cell activation plays an important role in lesion development7. Best known leukocyte activators are the highly 
conserved toll-like receptors (TLR), which are expressed on both immune and non-immune cells8. Several TLR 
subfamilies have been linked to atherosclerotic lesion initiation and progression, of which TLR2 and TLR4 have 
been the most extensively studied9. Although TLR5 has been linked to inflammation in a variety of inflammatory 
diseases including atherosclerosis10–13, the role of hematopoietic TLR5 deficiency in atherosclerotic plaque for-
mation remains unclear.
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TLR5 is an extracellular receptor for bacterial Flagellin and ubiquitously expressed in almost all tissue types14. 
In addition to one or more exogenous stimuli, most TLRs also respond to specific endogenous ligands15. Whereas 
a broad variety of endogenous ligands have been described for most TLRs9, an equivalent for TLR5 is lacking. 
Since many exogenous TLR ligands are expressed in (human) atherosclerotic lesions16, Flagellin may also have a 
role in the development of atherosclerosis in the current study17. However, since TLR5 is an important contribu-
tor in diseases characterized by sterile inflammation (like cardiac ischemia-reperfusion injury11 and rheumatoid 
artritis18), it is to be expected that both endogenous as well as exogenous ligands can lead to TLR5-dependent 
inflammation.
In addition to specific tissue cells, TLR5 is also present on different immune cells19–21, of which macrophages 
and T-cells are of main importance in the context of atherosclerosis. Upon activation of the TLR5 receptor, 
MyD88 recruitment and activation of different intracellular kinases eventually leads to nuclear localization of 
NF-κB, resulting in a pro-inflammatory respons22. Since imbalanced inflammation is key in the development and 
progression of atherosclerosis, we investigated whether monocytes and T-cells lacking TLR5 differ in migratory 
and inflammatory behavior and whether hematopoietic TLR5 deficiency influences atherosclerotic plaque for-
mation in vivo.
Materials & Methods
Animals. LDLr−/− mice were obtained from the local animal breeding facility, C57Bl6 mice from Charles 
River (Maastricht, The Netherlands) and TLR5 deficient (TLR5−/−) mice from Oriental Bioservices (Kyoto, 
Japan). Mice were maintained on sterilized regular chow (RM3; Special Diet Services, Essex, U.K.), drinking 
water was supplied ad libitum.
A blinded observer performed data acquisition and measurements. Animal experiments were performed 
at the animal facility of either the Gorlaeus laboratory, Leiden University or the Laboratory of Experimental 
Cardiology, University Medical Center Utrecht. All animal experiments were approved by the Ethical Committee 
on Animal Experimentation of Leiden University (Leiden, the Netherlands) or the University Medical Center 
Utrecht (Utrecht, the Netherlands) and conform to the ‘Guide for the care and use of laboratory animals’.
Bone marrow transplantation. To induce bone marrow aplasia, female LDLr−/− recipient mice were 
exposed to a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) total body irradiation using an Andrex Smart 225 
Röntgen source (YXLON International) with a 6 mm aluminum filter. The day after, donor bone marrow was 
isolated from male WT and TLR5−/− littermates by flushing the femurs and tibias. Irradiated female recipients 
received 0.5 × 107 bone marrow cells by tail vein injection. Drinking water was supplied ad libitum and supple-
mented with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B sulfate and 6.5 g/L sucrose) for 14 days, 
after which repopulation of the bone marrow has been completed.
After a recovery period of 6 weeks, animals were placed on a Western-type diet containing 0.25% cholesterol 
and 15% cacao butter (SDS) for 12 weeks, after which they were sacrificed.
Stimulation of bone marrow derived macrophages. Bone marrow cells were isolated from the tibias 
and femurs of male TLR5−/− and C57Bl/6 mice. To obtain bone marrow-derived macrophages, cells were cultured 
for 7 days in RPMI supplemented with 10% FCS, 100 U/mL penicillin/streptomycin, 0.1 mM nonessential amino 
acids, 1% pyruvate and 2 mM L-glutamine (Thermo Fisher Scientific) in the presence of 10 ng/mL macrophage 
colony-stimulating factor.
For in vitro stimulation, 0.5 × 106 macrophages were added per well (24-well cell culture plates (Greiner 
Bio-One)). Cells were stimulated with 1 ng/mL Flagellin Ultrapure (Invivogen, Toulouse, France) or 1 ng/mL 
LPS (Sigma Aldrich, Zwijndrecht, the Netherlands) as a positive control. After 24 hours, cells were harvested for 
RNA isolation.
RT-PCR. Total RNA was isolated from the stimulated WT and TLR5−/− macrophages using Trizol reagent 
according to manufacturer’s instructions (Invitrogen, Breda, the Netherlands). RNA was reverse transcribed 
using M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, Leon-Roth). The expression levels of induc-
ible nitric oxide synthase (iNOS), Arginase-1, monocyte chemoattractant protein-1 (MCP-1), C-C chemokine 
receptor type 2 (CCR2), and interleukin 6 (IL6) were analyzed by real time polymerase chain reaction (RT-PCR, 
Taqman, Applied Bioscience). Primer sequences are depicted in Table 1. The mRNA expression was determined 
relative to the average expression of three household genes: acidic ribosomal phosphoprotein PO (36B4), hypox-
anthine phosphoribosyltransferase (HPRT) and 60S ribosomal protein L27 (Rpl27).
Luminex. Circulating levels of IL6, IL17A and interferon-γ (IFN-γ) were determined by luminex according 
to the manufacturers protocol. A multiplex panel (eBioscience Mouse Th1/Th2 essential 6-plex and Mouse IL17A 
Simplex) was used in combination with the “Bio-Plex Multiplex system (Bio-Rad)” to perform luminex analyses.
Ex vivo proliferation and T-cell polarisation. Spleens were isolated from WT and TLR5−/− chimeras 
to assess ex vivo proliferation or C57Bl/6 WT mice to assess T-cell polarization. Spleens were gently squeezed 
through a 70 μm mesh cell strainer (Becton Dickinson, San Diego, CA, USA) to obtain a single cell suspension. 
Cells were washed and resuspended in RPMI1640 (supplemented with 10% FCS, 20 mM L-glutamine, 100 U/
ml penicillin and 100 μg/mL streptomycin) and seeded at a density of 3 × 105 cells/well in a 96 well u-bottom cell 
culture plate (Greiner Bio One, Alphen aan den Rijn, the Netherlands). Cells were stimulated for 72 hours with 
medium alone, 1 ng/mL Flagellin Ultrapure, 1 ng/mL Flagellin Ultrapure in combination with 2 μg/mL anti-CD3 
(eBioscience) or 2 μg/mL anti-CD3 in combination with 2 μg/mL anti-CD28 as a positive control. To assess pro-
liferation, cells were incubated with 0.5 μCi [3 H]Thymidine during the last 16 hours of 3 days in culture. To 
quantify thymidine incorporation the cells were washed with PBS and lysed with 0.1 M NaOH and cell-associated 
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radioactivity was determined by liquid scintillation counting. To assess T-cell polarisation, after 72 hours of stim-
ulation, 10 μg/mL Brefeldin-A was added overnight to retain the proteins inside the cell. The next morning cells 
were harvested for flow cytometric analysis.
Intracellular flow cytometry. Cultured T-cells were harvested, centrifuged and resuspended for intra-
cellular staining according to the manufacturers protocol (eBioscience). In short, cells were resuspended in PBS 
supplemented with 1% normal mouse serum and stained for the cell surface marker CD4 (BD Biosciences) for 
30 minutes in the dark at 4 °C. Cells were washed to remove unbound antibody and resuspended in IC fixation 
buffer. After 30 minutes, permeabilisation buffer was added, cells were centrifuged (1500 rpm, 5 min) and resus-
pended in permeabilisation buffer. Antibodies for intracellular antigens Tbet, IFN-γ, RORγt, IL17A and Foxp3 
(eBioscience) were added and incubated for 45 minutes at room temperature in the dark. Cells were washed twice 
in permeabilisation buffer and resuspended in flow cytometry staining buffer for cell acquisition (FACSCanto, 
BD Biosciences).
Flow cytometry. Blood, spleen and bone marrow cells were isolated from WT and TLR5−/− mice that had 
been fed a Western-type diet for 1 week. Bone marrow was isolated by flushing the femurs and tibias of WT and 
TLR5−/− mice with PBS. Subsequently, the cell suspension was gently filtered through a 70 μm cell strainer to 
obtain a single cell suspension (70 μm pores, BD Bioscience). Spleens were harvested and single-cell suspensions 
of splenocytes were prepared by gently mincing the spleen through a cell strainer (70 μm pores, BD Bioscience). 
Bone marrow cells and splenocytes were incubated at 4 °C with erythrocyte lysis buffer (155 mM NH4CL in 
10 mM Tris/HCL, pH 7.2) for 5 minutes. Cells were centrifuged for 5 minutes at 1500 rpm and then resuspended 
in lysis buffer to remove residual erythrocytes. Cells were washed twice with PBS. 50 μL whole blood, bone mar-
row (300.000 cells), or spleen cell suspensions (300.000 cells) were stained for the surface markers CD11B (eBi-
oscience), Ly6G (1A8) (Biolegend), Ly6C (Biolegend) and CCR2 (R&D Systems) and incubated for 30 minutes 
in the dark. Subsequently cells were either washed in PBS and subjected to flow cytometric analyses (Gallios, 
Beckman Coulter) or prepared for intracellular staining.
For intracellular assessment of cytokine content, cells were washed to remove unbound antibody and resus-
pended in IC fixation buffer (4° Celsius). After 60 minutes, cells were centrifuged (1500 rpm, 5 min) and resus-
pended in permeabilisation buffer, washed once more and resuspended in permeabilisation buffer. Antibodies for 
intracellular antigens IL10 and IL12 (eBioscience, San Diego, CA, USA) were added and incubated for 30 minutes 
at room temperature in the dark. Cells were washed twice in permeabilisation buffer and resuspended in flow 
cytometry staining buffer for cell acquisition (Gallios, Beckman Coulter). FACS data were analyzed with Kaluza 
software (Beckman Coulter) and gated according to the strategy depicted in supplemental Fig. 1.
Histological analyses. Cryosections of the aortic root (10 μm) were collected and stained with Oil-red-O 
for morphometric analyses. Corresponding sections on separate slides were used for immunohistochemical 
stainings. Macrophages were stained with an antibody directed against MOMA-2 (monoclonal rat IgG2b, dilution 
1:50; Serotec, Oxford, United Kingdom). Goat anti-rat IgG-AP (dilution 1:100; Sigma, St. Louis, MO) was used 
as a secondary antibody and NBT-BCIP (Dako, Glostrup, Denmark) as an enzyme substrate. CD4+ T-cells were 
stained using CD4 (monoclonal rabbit, dilution 1:50; Cell Marque, Darmstadt, Germany). BrightVision poly-AP 
anti-rabbit (Immunologic, Duiven, The Netherlands) was used as a secondary antibody and liquid permanent red 
(DAKO) as an enzyme substrate. CD8+ T-cells were stained using CD8a (monoclonal rat IgG2a,λ, dilution 1:50, 
eBioscience). The ImmPRESS HRP anti-Rat IgG, Mouse adsorbed (Peroxidase) Polymer Detection Kit (Vector, 
Burlingame, CA, USA) was used as a secondary antibody and DAB (Sigma, St. Louis, MO, USA) as an enzyme 
substrate. Collagen was visualized by a Masson’s trichrome staining (Sigma). The section with the largest lesion 
and at least four flanking sections were used to determine lesion size. At least two flanking sections were used to 
analyse macrophage, T-cell and collagen content. The percentage of macrophages and collagen in the lesions was 
determined by dividing the area positive for MOMA-2 or collagen by the total lesion surface area. Necrotic core 
size was determined in the Oil-red-O stained sections and defined as an a-cellular, lipid-poor region. CD4+ and 
CD8+ T-cells were manually counted and expressed as counts/mm2.
Histological analyses were performed in a blinded fashion using a Leica DMRE Microscope equipped with a 
Leica DC500 camera and Qwin quantification software (Leica, Rijswijk, the Netherlands). Histological analyses of 
Gene Forward Reverse
iNOS CCTGGTACGGGCATTGCT GCTCATGCGGCCTCCTTT
Arginase-1 TGGCAGAGGTCCAGAAGAATGG GTGAGCATCCACCCAAATGACAC
MCP-1 AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG
CCR2 AGAGAGCTGCAGCAAAAAGG GGAAAGAGGCAGTTGCAAAG
IL6 AGACAAAGCCAGAGTCCTTCAGAGA GGAGAGCATTGGAAATTGGGGTAGG
36B4 CTGAGTACACCTTCCCACTTACTGA CGACTCTTCCTTTGCTTCAGCTTT
HPRT TACAGCCCCAAAATGGTTAAGG AGTCAAGGGCATATCCAACAAC
Rpl27 CGCCAAGCGATCCAAGATCAAGTCC AGCTGGGTCCCTGAACACATCCTTG
Table 1.  Primer sequences. iNOS: inducible Nitric Oxide Synthase, MCP-1: monocyte chemoattractant 
protein-1, CCR2: C-C chemokine receptor type 2 (CCR2), IL6: interleukin 6, 36B4: acidic ribosomal 
phosphoprotein PO, HPRT: hypoxanthine phosphoribosyltransferase, Rpl27: 60S ribosomal protein L27.
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CD4+ and CD8+ T-cell quantification were performed on an Olympus BX53 microscope equipped with a DP71 
camera and CellSens quantification software (Olympus Corporation, Tokyo, Japan).
Statistical analysis. Data are expressed as mean ± standard error of the mean (SEM). Data distribution was 
evaluated using a Shapiro-Wilk test. A two-tailed student’s t-test was used to compare individual groups if data 
were normally distributed, whereas non-parametric data were analyzed using a Mann-Whitney U test. Multiple 
groups were compared by one-way ANOVA with a post-hoc two-tailed student’s t-test between significantly dif-
ferent groups. A level of p < 0.05 was considered significant. Statistical analyses were performed using GraphPad 
Prism 6.
Results
Absence of TLR5 affects migratory potential of macrophages in vitro. To study the effect of 
TLR5 signaling on immune cells, bone marrow derived macrophages from WT and TLR5−/− mice were stim-
ulated ex vivo with the TLR5 ligand Flagellin. Cells stimulated with LPS served as a positive control. As meas-
ured by iNOS and Arginase I expression, no preferential skewing towards either M1 (8.0*10−5 ± 4.7*10−5 vs. 
6.0*10−5 ± 7.3*10−6; p = 0.69, Fig. 1A) or M2 (8.0*10−5 ± 8.9*10−6 vs. 7.0*10−5 ± 1.8*10−5; p = 0.32, Fig. 1B) 
phenotype was observed upon stimulation with Flagellin. Already at baseline, TLR5−/− macrophages showed 
a lower expression of the potent monocyte chemoattractant MCP-1 (0.103 ± 0.015 in WT vs. 0.046 ± 0.014 A.U. 
in TLR5−/−; p = 0.013, Fig. 1C). Upon stimulation with Flagellin, the expression of MCP-1 increased only in 
WT macrophages (0.249 ± 0.071 in WT vs. 0.070 ± 0.013 A.U. in TLR5−/−; p = 0.0025). The expression of the 
MCP-1 receptor CCR2 was also lower in TLR5−/− macrophages at baseline (6.0*10−4 ± 4.8*10−5 in WT vs. 
2.3*10−4 ± 7.8*10−5 A.U. in TLR5−/−; p = 0.0069, Fig. 1D), but showed no further increase upon exposure to 
Flagellin in either WT (6.0*10−4 ± 4.8*10−5 vs. 7.1*10−4 ± 3.9*10−5 A.U.; p = 0.13) or TLR5−/− macrophages 
(2.3*10−4 ± 7.8*10−5 vs. 2.4*10−4 ± 5.3*10−5 A.U.; p = 0.92). In addition, expression levels of IL6 were sig-
nificantly higher in WT macrophages at baseline (1.4*10−4 ± 9.5*10−6 in WT vs. 6.0*10−5 ± 5.1*10−6 A.U. 
in TLR5−/−; p = 0.0003, Fig. 1E) and did marginally increase upon Flagellin stimulation in WT macrophages 
(1.4*10−4 ± 9.5*10−6 vs. 2.1*10−4 ± 2.9*10−5 A.U.; p = 0.06).
In vitro TLR5 stimulation induces regulatory T-cell differentiation. In addition to cells of the mye-
loid lineage, we observed expression of TLR5 in ≈14% of CD4+ T-cells, 44% of activated T-cells and 60% of the 
regulatory T-cells (data not shown). The effect of TLR5 signaling on CD4+ T-cell polarisation was studied by 
stimulating C57Bl/6 derived T-cells with Flagellin in the absence or presence of αCD3. Stimulation with a com-
bination of αCD3 and αCD28 served as a positive control. The number of regulatory T-cells was mildly induced 
upon exposure to Flagellin alone (2455 ± 74 vs. 2807 ± 109; p = 0.056, Fig. 2A) or in combination with αCD3 
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Figure 1. In vitro polarisation and migratory potential of macrophages. Stimulation of WT and TLR5−/− 
MCSF-derived macrophages with Flagellin or LPS did not induce significant differences in iNOS (A) and Arg-1 
(B) gene expression between both groups. Already at baseline, WT macrophages showed higher mRNA levels 
of MCP-1 (C), CCR2 (D) and IL6 (E), of which the expression of MCP-1 and IL6 increased upon Flagellin 
stimulation. No such increase was observed in TLR5−/− macrophages upon stimulation with Flagellin. The 
expression of CCR2 was also different at baseline between both groups, but no change in expression level 
was observed after stimulation with Flagellin (D); n = 4 per group. WT: wildtype, TLR5−/−: toll-like receptor 5 
knockout, #p < 0.05, ##p < 0.01, ###p < 0.001, **p < 0.01, ***p < 0.001.
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(2448 ± 306 vs. 3100 ± 124; p = 0.14). The number of T-helper 1 (Th1) cells decreased upon Flagellin stimula-
tion alone (22196 ± 203 vs. 19552 ± 150; p = 0.0005), Fig. 2B), but increased when exposed to a combination of 
Flagellin and αCD3 (181764 ± 2777 vs. 279000 ± 4879; p < 0.0001). Exposing CD4+ T-cells to Flagellin alone 
did not affect the number of T-helper 17 (Th17) cells (23064 ± 86 vs. 22385 ± 522; p = 0.27, Fig. 2C), but when 
exposed to a combination of Flagellin and αCD3 the number of Th17-cells robustly increased (160854 ± 1439 vs. 
199392 ± 4142; p = 0.0001).
Hematopoietic TLR5 deficiency reduces plaque size, macrophage area and necrotic core in 
LDLr−/− mice. To assess the effect of hematopoietic TLR5 deficiency on atherosclerotic lesion development, 
TLR5−/− bone marrow chimeras were generated. Plasma cholesterol and body weight were monitored during the 
experiment and did not significantly differ between WT and TLR5−/− chimeras (data not shown). After 12 weeks 
of high fat diet feeding, mice were sacrificed and atherosclerotic lesion size in the aortic root was analyzed. In 
TLR5−/− chimeras, lesion size was markedly reduced by ≈25% (1030*103 ± 63*103 in WT vs. 792*103 ± 61*103 μm2 
in TLR5−/−; p = 0.013, Fig. 3A), whereas collagen content as a percentage of total plaque area was not different 
between both groups (24.0 ± 2.0 in WT vs. 24.0 ± 1.2% in TLR5−/−; p = 0.99, Fig. 3B). The decrease in lesion size 
was accompanied by a reduction in macrophage area (81.3 ± 12.0 in WT vs. 44.2 ± 6.6 μm2 in TLR5−/−; p = 0.011, 
Fig. 3C), however lesions in TLR5-/- chimeras did not show a difference with respect to the percentage of mac-
rophage area (7.4 ± 1.1 in WT vs. 5.2 ± 0.8% in TLR5−/−; p = 0.10, Fig. 3D). Despite the observed decrease in splenic 
T-cell content we did not observe a difference in the number of CD4+ T-cells accumulated in the plaques of TLR5−/− 
mice (309 ± 89 in WT vs. 498 ± 338/mm2 in TLR5−/−; p = 0.17, Fig. 3E). Similarly, no difference was observed in the 
number of CD8+ T-cells (38 ± 30 in WT vs. 69 ± 40/mm2 in TLR5−/−; p = 0.16, Fig. 3F). In agreement with smaller 
lesion size, necrotic core size was reduced (21.6 ± 2.7 in WT vs. 14.7 ± 1.9% in TLR5−/−; p = 0.046, Fig. 3G).
The numbers of circulating monocytes, T-cells and their subsets are influenced by TLR5 deficiency. 
One week after feeding WT and TLR5−/− mice a Western-type diet, flow cytometry was used to assess several 
monocyte subsets and receptor expression on blood and bone marrow. We observed that TLR5-/- mice displayed 
a decreased number of circulating pro-inflammatory Ly6Chigh monocytes (498 ± 75 in WT vs. 367 ± 57 cells/uL in 
TLR5−/−; p = 0.01, Table 2). In addition, TLR5−/− circulating monocytes showed a decrease in pro-inflammatory 
IL12 staining (140 ± 55 in WT vs. 38 ± 8 cells/uL in TLR5−/−; p = 0.003, Table 2). In the bone marrow, 
we observed a decrease in the number of monocytes as a percentage of all viable cells (11.4 ± 0.5 in WT vs. 
9.1 ± 0.5% in TLR5−/−; p < 0.0001, Table 2) and specifically, a decrease in Ly6Chigh monocytes (10.1 ± 0.7 in WT 
vs. 7.7 ± 0.4% in TLR5−/−; p = 0.003, Table 2). Both, blood and bone marrow showed a decrease in the percentage 
of CCR2+ cells.
T-cell subsets were determined in the hematopoietic TLR5−/− mice at the end of the experiment. The number 
of CD4+ T-cells as a percentage of total splenocytes was lower in TLR5−/− mice (32.9 ± 2.2 in WT vs. 22.4 ± 1.0% 
in TLR5−/−; p = 0.0013, Fig. 4A), as was the percentage of activated CD4+ CD25+ T-cells (32.3 ± 2.1 in WT 
vs. 21.0 ± 1.2% in TLR5−/−; p = 0.0018, Fig. 4B). Similarly, TLR5−/− mice displayed lower percentages of Tregs 
(13.7 ± 2.4 in WT vs. 6.8 ± 0.6% in TLR5−/−; p = 0.0087; Fig. 4C) and a slightly lower percentage of Th1-cells 
(11.8 ± 3.1 in WT vs. 6.2 ± 0.6% in TLR5−/−; p = 0.13, Fig. 4D).
Ex vivo T-cell proliferation was performed to assess complete replacement of T-cells upon bone marrow trans-
plantation (Fig. 4E). Proliferation under control, non-stimulatory conditions did not differ between WT and 
TLR5−/− cells (p = 1.00). Proliferation upon stimulation with Flagellin alone or Flagellin in combination with 
αCD3 is displayed as fold induction to control proliferation. Stimulation with Flagellin led to an increased prolif-
eration index in WT mice (3.8 ± 1.1 upon stimulation vs. 1.0 ± 0.3 in non-stimulatory conditions; p = 0.03), but 
did not in TLR5−/− mice (p = 0.96). In the presence of both Flagellin and αCD3, T-cell proliferation was robustly 
induced in WT (50.4 ± 18.7 upon stimulation vs. 1.0 ± 0.3; p = 0.03), but not in TLR5−/− mice (1.2 ± 0.4 upon 
A B C
- Flag - Flag αCD28
0
1.0×103
2.0×103
3.0×103
4.0×103
Treg
C
D
4+
Fo
xp
3+
Tr
eg
+ αCD3
p=0.06
**
- Flag - Flag αCD28
0
1.0×104
2.0×104
3.0×104
2.0×105
3.0×105
4.0×105
5.0×105 Th1
C
D
4+
Tb
et
+
IF
N
γ+
Th
1
ce
lls
+ αCD3
***
- Flag - Flag αCD28
0
1.0×104
2.0×104
3.0×104
1.5×105
2.0×105
2.5×105 Th17
C
D
4+
R
O
R
γ t
+
IL
17
a+
Th
17
ce
lls
+ αCD3
******
***
Figure 2. In vitro polarisation of T-cells. Exposure of Flagellin to WT CD4+ T-cells either in the presence 
or absence of αCD3 resulted in a mild but insignificant induction in the number of Tregs (A). The number of 
Th1-cells decreased upon Flagellin stimulation only (B), whereas no change was observed in Th17-cells (C). In 
the presence of both Flagellin and αCD3, the induction of Th1- and Th17-cells robustly increased (B,C); n = 3 
per group. WT: wildtype, Tregs: regulatory T-cells, Th1-cells: T helper type 1 cells, Th17: T helper type 17 cells, 
**p < 0.01, ***p < 0.001.
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Figure 3. Atherosclerotic plaque size and composition. After 12 weeks of high-fat diet, the atherosclerotic 
plaque area was significantly larger in WT mice compared to TLR5−/− mice (A). No difference between both 
groups was observed with respect to collagen content (B), yet the plaque of TLR5−/− mice showed a decrease 
in macrophage influx (C,D). Although not significant, TLR5−/− mice showed higher numbers of CD4+ (E) 
and CD8+ T-cells (F). The necrotic core expressed as a percentage of the plaque was significantly higher in WT 
mice (G); n = 12–13 per group (5-8 for CD4-8 staining). WT: wildtype, TLR5−/−: toll-like receptor 5 knockout, 
*p < 0.05.
Blood (cells/μl) Bone Marrow (% of viable cells)
Cell (sub)type Wildtype TLR5−/− p Wildtype TLR5−/− p
Monocytes 776 ± 124 621 ± 97 = 0.06 11.4 ± 0.5 9.1 ± 0.5 ↓  < 0.0001
Ly6Chigh mono 498 ± 75 367 ± 57 ↓ 0.01 10.1 ± 0.7 7.7 ± 0.4 ↓ 0.0002
Ly6Clow mono 291 ± 91 274 ± 49 = 0.73 1.3 ± 0.2 1.4 ± 0.1 = 0.54
CCR2+ mono 176 ± 36 154 ± 33 = 0.35 7.2 ± 0.4 5.8 ± 0.3 ↓ 0.0006
CCR2+ Ly6Chigh mono 102 ± 24 90 ± 16 = 0.37 6.5 ± 0.5 5.0 ± 0.3 ↓ 0.0005
Ratio Ly6Chi/low 1.83 ± 0.53 1.34 ± 0.04 = 0.08 8.1 ± 1.8 5.7 ± 0.15 ↓ 0.02
IL12+ mono 140 ± 55 38 ± 8 ↓ 0.003 n.d. n.d.
IL10+ mono 307 ± 69 249 ± 51 = 0.16 n.d. n.d.
Ratio IL12/IL10 0.45 ± 0.10 0.16 ± 0.05 ↓ 0.0003 n.d. n.d.
Table 2.  Monocyte subsets and their pro-inflammatory and migratory protein levels. Mono (=monocytes) 
were selected as CD11b+, Ly6G−, Ly6C+ cells. n.d. = not determined.
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stimulation vs. 1.0 ± 0.3; p = 0.71). Flagellin-independent proliferation was normal in TLR5−/− T-cells as shown 
by αCD3/αCD28-induced proliferation (proliferation index 85.3 ± 55 in TLR5−/− and 96.7 ± 23 in WT, data not 
shown).
Hematopoietic TLR5 deficiency influences pro-inflammatory cytokine levels. Luminex was 
used for the quantification of pro-inflammatory cytokine levels in plasma of WT and TLR5−/− mice at sacrifice. 
Compared to WT animals, significantly lower levels of IL6 (36.4 ± 5.6 in WT vs. 15.1 ± 2.2 pg/mL in TLR5−/−; 
p = 0.0029, Fig. 5A) and IL17A (4.1 ± 1.8 in WT vs. 1.0 ± 0.4 pg/mL in TLR5−/−; p = 0.028, Fig. 5B) were detected 
in plasma of TLR5−/− mice. Plasma IFN-γ levels were relatively low and did not allow us to reliably calculate the 
concentration. Therefore, we used mean fluorescence intensity (MFI) to compare both groups, which showed 
slightly decreased IFN-γ levels in TLR5−/− mice compared WT mice (39.7 ± 9.8 in WT vs. 20.9 ± 5.4 in TLR5−/− 
MFI; p = 0.09, Fig. 5C).
Figure 4. Splenic T-cell numbers, subsets and proliferation indices. The number of CD4+ T-cells as 
a percentage of total splenocytes was higher in WT mice compared to TLR5−/− mice (A), similar to the 
percentage of activated CD4+ CD25+ T-cells (B). Tregs expressed as a percentage of total splenocytes were 
significantly higher in WT mice (C) and, yet insignificantly, so was the percentage of Th1-cells (D). T-cells 
isolated from the spleen were used for proliferation indices in both groups (E). No differences were observed at 
baseline. Upon stimulation with Flagellin alone the proliferation index was increased in only the WT T-cells, 
an effect that was even more pronounced in the presence of αCD3. No such differences were observed with 
Flagellin either in the presence or absence of αCD3 with the TLR5−/− T-cells; n = 4–6 per group. TLR5−/−: 
toll-like receptor 5 knockout, WT: wildtype, Tregs: regulatory T-cells, Th1-cells: T helper type 1 cells, *p < 0.05, 
**p < 0.01.
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Discussion
Over the past decades there has been a widespread interest in the role of TLRs in the onset and progression of 
cardiovascular diseases. In atherosclerosis, TLR2 and TLR4 have been the most prominently studied9 and evi-
dence for the role of TLR5 has been previously shown12,13. In this regard, the current paper is the first to show that 
hematopoietic TLR5 deficiency attenuates atherosclerosis formation in LDLr−/− mice. In addition, the plaques 
of these mice contain less macrophages and a smaller necrotic core compared to mice that received WT bone 
marrow. These findings are in line with previous studies that show the effect of TLR5 in atherosclerotic plaque 
formation and inflammatory cell accumulation12,13. It also confirms the observation that inflammation – and 
TLRs in particular – are key drivers of atherosclerosis3,9,12.
In general, lack of TLRs is believed to decrease atherosclerotic burden through the impairment of 
pro-inflammatory signaling. In this respect, macrophages from WT mice showed an increased expression of 
MCP-1 and IL6 upon Flagellin stimulation, whereas no difference was observed upon stimulation of TLR5 defi-
cient macrophages. Also, TLR5−/− mice showed a decrease in circulating and bone-marrow derived Ly6Chigh 
monocytes and a decrease in pro-inflammatory cytokine production (IL10, IL12). Correspondingly, plasma levels 
of several pro-inflammatory cytokines were higher in WT mice than in TLR5−/− bone marrow chimeras.
The fact that we observe a decrease in the Ly6Chigh monocyte pool in both the bone marrow and circula-
tion suggests that monocyte recruitment to the plaque may be impaired. In addition, CCR2 expression on the 
bone marrow monocyte pool is significantly decreased in TLR5 deficient mice, which partly reflects previous 
research showing that CCR2 deficiency attenuates macrophage influx into the plaque23. Decreased macrophage 
CCR2 expression could have had a similar effect in the current manuscript. In addition to the impairment in 
pro-inflammatory signaling, this may very well be one of the primary mechanisms in the reduction of atheroscle-
rotic plaque formation. These findings are in accordance with previous studies showing that TLR5 stimulation 
of mouse endothelial cells enhanced the expression of pro-inflammatory molecules and increased the adhesive 
and migratory capacity for monocytes12. In addition, TLR5 inhibition showed decreased serum levels of several 
pro-inflammatory cytokines13. Similarly, ApoE−/−TLR4−/− mice on high-cholesterol feeding showed a reduc-
tion in serum MCP-1 levels, plaque size and macrophage infiltration when compared to ApoE−/− mice24. Again, 
this emphasizes the importance of migratory proteins (MCP-1, IL6, etc.) in atherogenesis and inflammatory cell 
deposition5,6,23,25.
In addition to TLR5 being abundantly expressed on cells of myeloid origin, we observed expression of TLR5 
on CD4+ T-cells as well. When exposing T-cells to Flagellin in a non-inflammatory condition, an increase in the 
number of Tregs and a decrease in Th1-cells were observed. These data are similar to a previous study showing 
that TLR5 stimulation enhances the suppressive capacity of regulatory T-cells26. However, when performing these 
experiments under more inflammatory conditions by adding αCD3 to simulate antigen-T-cell receptor interac-
tion, the suppressive effect of Tregs was lost and actually proliferation of pro-atherogenic Th1- and Th17-cells was 
stimulated. This implicates a pro-atherogenic effect of stimulation of TLR5 on T-cells in a pro-inflammatory envi-
ronment, like observed in atherosclerosis. Indeed, this was reflected in vivo by lower numbers of Tregs, activated 
CD4+ CD25+ cells and Th1-cells and decreased IL6, IL17A and IFN-γ plasma levels in TLR5−/− bone marrow 
chimeras. Despite this general effect on CD4+ T-cells, no significant reduction in the number of CD4+ or CD8+ 
T-cells in the atherosclerotic plaque was observed.
Apart from their importance as pattern recognition receptors (PRR) of exogenous (mostly bacterial) ligands, 
TLRs can also potently respond to specific disease-associated endogenous ligands15. Whereas a broad variety 
of endogenous ligands have been described for several TLRs9, an equivalent for TLR5 is lacking. Since many 
exogenous TLR ligands are expressed in (human) atherosclerotic lesions16, Flagellin may indeed be (partially) 
responsible for the results observed in the current study, implicating a role of (subclinical) infection in the devel-
opment of atherosclerosis17. However, this phenomenon may be debated on by accumulating evidence show-
ing that TLR5 also plays an important role in diseases characterized by sterile inflammation, such as cardiac 
ischemia-reperfusion injury11 and rheumatoid artritis18.
Although it remains unclear which ligand is responsible for the observed effect in the current study, we do 
show the importance of hematopoietic TLR5 deficiency in the early stage of atherosclerosis formation. Whether 
this also holds true for a model of atherosclerosis with larger and more complex lesions remains to be elucidated. 
Figure 5. Plasma levels of pro-inflammatory cytokines. Plasma levels of IL6 (A) and IL17A (B) determined 
by luminex were significantly lower in TLR5−/− mice. Yet insignificant, also the plasma levels of IFN-γ were 
lower in TLR5−/− compared to WT mice (C); n = 8–10 mice per group. TLR5−/−: toll-like receptor 5 knockout, 
WT: wildtype, IL: interleukin, IFN-γ: interferon γ, *p < 0.05, **p < 0.01.
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In this regard, hematopoietic TLR2 deficiency has also been shown to be important in the early stage of athero-
sclerosis formation, but was not evident when feeding mice a 1.5% instead of a 0.15% cholesterol-enriched diet27. 
Moreover, although baseline TLR5 deficiency was able to attenuate atherosclerotic plaque formation, from a clin-
ical perspective it remains of interest to see whether TLR5 inhibition at a later stage would also be able to reduce 
or stabilize already manifest atherosclerosis.
Conclusion
In conclusion, the present manuscript is one of the first to show that hematopoietic TLR5 deficiency in mice 
attenuates atherosclerotic plaque development through decreased macrophage accumulation and defective T-cell 
responsiveness. Still, more knowledge has to be gathered on the possibility to antagonize TLR5 signaling to 
reduce or stabilize previously established atherosclerotic lesions.
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